EGFL7 and hepatocellular carcinoma: In this study, the VEGF, OPN, Egfl7, and AST indexes decreased in both groups after treatment, with group A decreasing more significantly than group B, implying that apatinib combined with camrelizumab in the treatment of advanced HCC can further improve the outcomes.